Articles

Breast cancer patients treated with chemotherapy are at risk for mild cognitive deficits following treatment, according to a large meta-analysis conducted by researchers at Moffitt Cancer Center. Analysis showed that on average, study participants experienced mild impairments in verbal abilities and visuospatial abilities. Study authors stated that cognitive functioning varied across survivors. Some patients reported no impairments, and others reported more severe deficiencies.

According to research presented at the 2012 Chicago Multidisciplinary Symposium in Thoracic Oncology, Hispanics/Latinos with non–small cell lung cancer (NSCLC) have a higher overall survival compared to non-Hispanic white patients.

Men with prostate cancer treated with hormone therapy intermittently respond as well as those treated continuously. The stop-start treatments allows for quality-of-life benefits, too, according to a new study published in the New England Journal of Medicine.

Study results showed the benefits for patients treated with intermittent therapy included fewer urinary problems and hot flushes, as well as improved libido and erectile function.

In the first week following breast cancer surgery, women are up to 3 times more likely to have severe pain if they already experience other painful conditions, such as arthritis, low back pain, and migraine, according to a Cancer Research UK study published in the British Journal of Cancer.

According to a detailed comparison of the SEER-17 (Surveillance, Epidemiology and End Results) for the years 1999-2003 and the years 2004-2008, patients with stage I, non–small cell lung cancer (NSCLC) treated with radiation therapy have an increased median survival of 21 months (2004-2008) compared with 16 months (1999-2003). Furthermore, the percentage of patients who receive no treatment for NSCLC declined from 20% for the years 1999-2003 to 16% for the years 2004-2008.

Amgen is a pioneer in the field of biologic medicines and our mission is to serve patients.

The pursuit of science-based medicines that restore health or even save lives is fundamental to our values. Our primary focus is to continue discovering, developing, manufacturing and commercializing innovative medicines to treat grievous illnesses. Amgen’s leading position in biotechnology, long-standing commitment to patient safety and leadership in manufacturing high quality biologic medicines mean that Amgen is equipped to develop and produce safe and effective biosimilars.

Patients with recurrent glioblastoma at The Ohio State University Comprehensive Cancer Center – Arthur G. James Cancer Hospital and Richard J. Solove Research Institute (OSUCCC–James) are the first to experience a novel treatment using a high-tech device designed to help control brain tumors that might otherwise be untreatable.

Following surgery, chemotherapy and radiation, patients wear the electrical “helmet” up to 18 hours a day. It bombards the brain with electrical currents. Patients say the machine is silent and easy to use.